🔬 Exciting opportunity alert! Join us at the Pelotonia Scientific Symposium featuring groundbreaking research from Pelotonia-funded scholars. Learn about the impact of research funding and support their work. Register now for this exciting event!
go.osu.edu/CpjD

Very happy to be representing Qin Ma BMBL lab and Pelotonia Institute for Immuno-Oncology at AACR this year. Very excited to see some of the new computational work on TME and immune-oncology. Stop by my poster 4879 Monday morning and see some of our ongoing work with Gunderlab studying TLSs in ST data.

#FollowFriday Dr. Zihai Li is the Founding Director of the Pelotonia Institute for Immuno-Oncology at The James. He's a great leader, wonderful friend and colleague and has done some outstanding science in the areas of TGFβ, the tumor microenvironment and the impact of sex…

Join us today for #PIIO research in progress by Jacob Kaufman, entitled 'Differentiation phenotypes induce distinct immunotherapy resistance mechanisms in STK11-deficient lung cancer.’

Many thanks to @Pelotnia funding partner, Pharmavite, for visiting the #PIIO to learn more about the work we do to advance #ImmunoOncology . Special thanks to Dr. Hakimeh Ebrahimi-Nik for giving updates on her research, which focuses on the functional dynamics of #CD8 #Tcells .

Groundbreaking research at The James resulted in FDA approval of tumor-infiltrating lymphocytes for metastatic melanoma. Congrats to Drs. Kai He, Richard Wu, Joal Beane, Claire Verschraegen & Kari Kendra on this notable achievement! go.osu.edu/Cn9B

Join us today for #PIIO research in progress by Dr. No Joon Song, entitled 'Natural killer cells regulate distinct CD8+ T cell differentiation program in cancer and contribute to resistance against immune checkpoint blockers.’

Join us today for #PIIO - Medical Oncology recruitment seminar by Dr. Mona Li, entitled 'Targeting Tumor Cell Vulnerabilities to modulate immune responses in cancer patients.’

Don't forget!! Team Buckeye Registration Incentive ends TODAY. Register as Rider, Challenger, or Volunteer for Team Buckeye - PIIO and receive 2 unique donations by tonight at 11:59 p.m. EST, and you'll be entered to win a bonus donation! Don't miss out! pelotonia.org/sign-in?intent…

Join us today for #PIIO research in progress by Dr. Andy Gunderson (Gunderlab), entitled 'Modulating cancer associated fibroblast phenotypes to improve tumor immunity.’

Congrats to #PIIO founding director, Dr. @zihai Li, who received the Faculty Research Award at the Dean’s Excellence Award Gala! The Li Lab is doing groundbreaking work on #immune regulation in #cancer . Kudos to Carol Bradford & The Ohio State University College of Medicine for hosting an inspiring event!

Throwback shoutout to #PIIO member Deb Sundi for being awarded the OSU Physician Scientist Retention in Research with his project titled “Implications of Heterogeneous Immune Infiltration in Bladder Cancer.” Congratulations Dr. Deb Sundi!

Join us today for #PIIO research in progress by Dr. Stan Huang (Stan Huang Lab), entitled 'Metabolic Barriers in Tumor Macrophages for Immunotherapy.’

Congratulations, Jess and Debasmita Mukherjee‼️

New pub in Nature Communications by #PIIO member Zihai Li, MD, PhD & collaborators who highlights the critical role of glucose-regulated protein 94 (gp96) in the maturation and function of natural killer (NK) cells, which is essential for cancer surveillance in mice.
go.osu.edu/Ckse

Join us today for #PIIO research in progress by Dr. Debasish Sundi (Deb Sundi), entitled 'Bladder cancer immune microenvironment - urine derived lymphocytes and spatial heterogeneity .'

#PIIO member Dubey lab's work in Cancer Research Communications
highlights effectiveness in combining low-dose paclitaxel with pembrolizumab in patients with platinum-refractory urothelial carcinoma, showing a notable objective response rate & progression-free survival.
go.osu.edu/Cksa

CheckMate9LA update in Journal for ImmunoTherapy of Cancer by #PIIO member Dr. David P Carbone & collaborators reports that #NSCLC patients treated with nivo plus ipi with chemotherapy show long term benefit. Data supports this as first-line therapy in metastatic/recurrent NSCLC.
go.osu.edu/CksX